Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 4, 2025
- Accession no.
- 0001193125-25-196315
- Filed
- Sep 4, 2025
- Trade date
- Sep 2-3, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.41M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Common Stock | MOption exerciseAcquired | +20,000 | $5.05 | +$101,000 | 27,681 | Direct | |
| Sep 2, 2025 | Common Stock | SSaleDisposed | −15,070 | $70.38F3 | −$1,060,626.6 | 12,611 | Direct | |
| Sep 2, 2025 | Common Stock | SSaleDisposed | −4,930 | $70.84F4 | −$349,241.2 | 7,681 | Direct | |
| Sep 2, 2025 | Common Stock | AGrant or awardAcquired | +228 | $71.38F6 | +$16,274.64 | 7,909 | Direct | |
| Sep 2, 2025 | Common Stock | AGrant or awardAcquired | +228 | $0.00 | $0 | 8,137 | Direct | |
| Sep 3, 2025 | Common Stock | FTax withholdingDisposed | −233 | $71.38F9 | −$16,631.54 | 7,904 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 1,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.715 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.72 to $71.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F6
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F9
The closing price on September 2, 2025 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.